Market Opportunity
INOVIQ's lead products in development are EXO-OC™ Ovarian Cancer screening test and CAR-Exosome therapy for Triple Negative Breast Cancer TNBC and other solid tumours.
The global cancer burden is significant with an estimated 50.6 million people living with cancer, 19.3 million new cases and 10.0 million deaths in 2020.1 The incidence of cancer is expected to rise to 28.4 million new cases by 2040 due to population aging and growth. The most common diagnosed cancers worldwide were breast 11.7% of all new cases, lung 11.4%, colorectal 10.0%, prostate 7.3% and stomach 5.6% cancers. Cancer is a leading cause of premature death with the highest burdens in China, Europe and North America. The cancer burden can be reduced by improved prevention, early detection, availability of cancer screening programs and effective treatment to improve patient outcomes and reduce mortality.
Ovarian Cancer Screening Market
There is no approved screening test for ovarian cancer detection in asymptomatic women. The anticipated target market is the existing breast cancer mammography cohort of women aged approximately 45-75 years old screened every 1-2 years. Across 9 major markets, and assuming the same 60% participation rate of eligible women, a screening test for ovarian cancer has the opportunity to reach over 240M women every 1-2 years. Earlier detection of ovarian cancer could improve patients’ survival from ~30% to 95%.
Triple Negative Breast Cancer Therapeutics Market
Across 9 major markets over 5M women are living with TNBC and over 600,000 women every year are diagnosed with TNBC and could potentially benefit from a novel therapeutic.
Beyond the markets described above, INOVIQ’s proprietary exosome platform can be used in the future to develop novel products for additional cancers that are difficult to diagnose and treat.
Exosomes Have Huge Potential as Novel Biomarkers for Multiple Diseases & Applications
Exosomes are small extracellular vesicles EVs released by all cells. They are nanometre-sized lipid membrane packages that encapsulate and protect from degradation DNA, RNAs and proteins. EVs and the messages they carry form part of the cell-to-cell communication system and play an important role in health and disease. Intercepting and reading EV messages has important applications in the research, diagnosis and treatment of many diseases, including: cancer, cardiometabolic, inflammatory, neurodegenerative and other diseases.
Clinical interest in exosomes has grown exponentially due to their commercial potential in drug delivery, disease diagnosis and treatment of cancer. Advancements in exosome research have been limited by slow, impure and inefficient traditional methods to isolate exosomes. There is an unmet need for fast, precise and scalable isolation of exosomes for research and commercial applications.
INOVIQ has developed a rapid and efficient way EXO-NET to isolate EVs from biofluids to intercept and decode the messages that they contain. This information can be used for assessing patient well-being or disease risk, diagnosis of disease, selecting the best treatment option, or monitoring a patient’s response to treatment.
